15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Bioventus Inc, 3 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $14.00 to $16.00, so the covering firms are broadly aligned. The average target of $15.00 sits 14% above the current $13.21. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.18 next quarter toward $0.91 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Strong Buy
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Bioventus Inc.
As of Jul, 3 of 3 firms rate BVS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
BVS EPS & revenue forecast
EPS · NEXT QUARTER
$0.18
Range $0.16 – $0.19 · 5 analysts · +17% YoY
Next period, 5 analysts expect Bioventus Inc to earn $0.18 a share (range $0.16 – $0.19), versus $0.15 a year earlier. Full-year consensus is $0.78, growing to $0.91 the year after.
REVENUE · NEXT QUARTER
$148.9M
Range $147.6M – $150.7M · 5 analysts · +7% YoY
Revenue is expected to reach $148.9M (range $147.6M – $150.7M), +7.4% year-over-year. Full-year consensus is $605.8M, rising to $646.3M next year.
Top analysts covering Bioventus Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BVS.
#1
Ross Osborn
Cantor Fitzgerald · Rank #139
Buy
$14.00+6.0% to target
Overall win rate
34%
+ Follow
#2
William Plovanic
Canaccord Genuity · Rank #190
Buy
$15.00+13.6% to target
Overall win rate
36%
+ Follow
#3
Michael Petusky
Barrington Research · Rank #322
Buy
$14.00+6.0% to target
Overall win rate
29%
+ Follow
#4
AN
Alexander Nowak
Craig-Hallum
Buy
$16.00+21.1% to target
Coverage
—
+ Follow
#5
CC
Caitlin Cronin
Canaccord Genuity
Buy
$15.00+13.6% to target
Coverage
—
+ Follow
BVS stock forecast FAQ
What is BVS's average 12-month price target?+
The 3 analysts with a live target average $15.00 for Bioventus Inc over the next 12 months, ranging from a $16.00 high to a $14.00 low.
Is BVS stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 3 analyst ratings, 3 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for BVS?+
The Street-high target is $16.00 (Craig-Hallum), and the Street-low is $14.00 (Barrington Research). The average of all 3 active targets is $15.00.
How many Wall Street analysts cover BVS?+
3 analysts have an active rating on Bioventus Inc, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering BVS?+
Among analysts who currently cover BVS, Ross Osborn of Cantor Fitzgerald has the strongest overall Quantellect track record (Rank #139). Their current call is Buy with a $14.00 target.
What is Bioventus Inc's projected EPS for next quarter?+
The consensus estimate is $0.18 per share (range $0.16 – $0.19) across 5 analysts. Full-year EPS is projected at $0.78, rising to $0.91 the following year.
How much revenue is Bioventus Inc expected to report next quarter?+
Consensus revenue is $148.9M (range $147.6M – $150.7M). Full-year revenue is projected at $605.8M, growing to $646.3M next year.
Have analysts been upgrading or downgrading BVS lately?+
As of Jul, 3 of 3 firms rate BVS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BVS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
